Author(s):
Taranjit Kaur, Charanjit Kaur, Iqbaljit Kaur, Parminderjit Kaur
Email(s):
parminderkaur.pk67@gmail.com
DOI:
10.52711/0974-360X.2021.01142 
Address:
TaranjitKaur1, Charanjit Kaur2, Iqbaljit Kaur3, Parminderjit Kaur2
1Department of Pharmaceutics, Rayat-Bahra Institute of Pharmacy, Hoshiarpur Punjab.
2Assistant Professor, Khalsa College of Pharmacy, Punjab, India.
3Assistant Professor, Lovely Professional University, Jalandhar.
*Corresponding Author
Published In:
Volume - 14,
Issue - 12,
Year - 2021
ABSTRACT:
Objective: The objective of the current research work was to prepare polymeric nanoparticles of gemcitabine hydrochloride and then incorporate the drug-loaded nanoparticles into an in-situ gelling system to provide dual sustained release effect, whereby the duration of action, targeting action, dose as well as dose duration could be improved. Introduction: Gemcitabine hydrochloride is a first line therapy drug for the treatment of pancreatic cancer, which competes with new generations in the market, with its potential activity. The major physicochemical constraints and pharmacokinetics of gemcitabine hydrochloride such as poor permeability, less half-life, high dose has initiated many researchers to develop diverse modified release dosage forms. Materials and methods: Firstly, development of nanoparticles using chitosan and sodium TPP by ionic gelation method followed by dispersion of the suspended nanoparticles into thermo sensitive in situ gelling system of pluronic F-127 with carbopol 934. Results and discussion: The characterization and evaluation of the nanoparticles and its sol-gel system performed through particle size, zeta potential, TEM, XRD, DSC and other rheological properties like viscosity, gelation temperature and time. The % cumulative drug from optimized PNP’s (CTN7) andin situ gelling system (GIS5) was found to be 72% and 47% respectively after 24 hours. Conclusion: The development of gemcitabine hydrochloride nanoparticles incorporated into gel, used for the treatment of pancreatic cancer was unique and promising system for site specific dual sustained action.
Cite this article:
Taranjit Kaur, Charanjit Kaur, Iqbaljit Kaur, Parminderjit Kaur. Preparation and characterization of In Situ Gel of Gemcitabine Hydrochloride loaded Nanoparticles used for the treatment of Pancreatic Cancer. Research Journal of Pharmacy and Technology. 2021; 14(12):6609-6. doi: 10.52711/0974-360X.2021.01142
Cite(Electronic):
Taranjit Kaur, Charanjit Kaur, Iqbaljit Kaur, Parminderjit Kaur. Preparation and characterization of In Situ Gel of Gemcitabine Hydrochloride loaded Nanoparticles used for the treatment of Pancreatic Cancer. Research Journal of Pharmacy and Technology. 2021; 14(12):6609-6. doi: 10.52711/0974-360X.2021.01142 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-12-72
REFERENCES:
1. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. J of the Pancreas. 2007; 8:545–52.
2. SaifMW.Pancreaticneoplasmin: an update. J of the Pancreas,2011, 12(4), 316-21.
3. Sarasija S, Shyamala B. Nasal drug delivery: an overview. Indian J Pharm. Sci. 2005; 67:19-25.
4. Schenk M., Schwartz AG., Garabrant familial risk of pancreatic cancer. J Nat. Cancer Inst., 2001, 93, 640-44.
5. Nandini PT., Dojjad RC., Shivkumar HN., Dandagi PM. Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Delivery, 2015,22, 647-651.
6. Calvo P., Gonzalo T., Lollo G., Garcia-Fuentes M.Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl. Polymer Sci.,1997, 63, 125-32.
7. Zohra Z., Souad S., Hatem F. Preparation and characterization of polycaprolactone nanoparticles containing Griseofulvin. Int. J. Pharm., 2005, 294, 261-67.
8. Mehrotra A. Pandit JK.Critical process parameters evaluation of modified nanoprecipitation method on lomustine nanoparticles and cytostatic activity study on L132 human cancer cell line. J. Nanomedic. Nanotechnol., 2012,3, 1-8.
9. Parmar V. LumbhaniA. Development and evaluation of ion-dependent in situ nasal gelling systems of metoclopramide hydrochloride as an antimigraine model drug. Int. J. Latest Res. Sci. Tech.,2012, 1, 80-89.
10. Amudha M., Kumara K., Sundaram S.Biosynthesis and characterization of silver nanoparticles using the aqueous extract of vitex negundo. World J. Pharm. pharm. Sci., 2014, 3, 1385-93.
11. Venkateswarlu V.,Manjunath G.Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J control. Releas., 2004, 95, 627-38.
12. Pravin K., Rajendra A., Puneet KR.Mucoadhesivein situ gels of local anaesthetic for periodontia. Der Pharmacia. Letter.,2010, 2, 28-39.
13. Khan S., Gajbhiye C., Singhavi D., YeoleP. In situ Gel of metoprolol tartrate: physicochemical characterization in vitro diffusion and histological studies. Indian J. Pharm. Sci., 2012, 74, 564-70.
14. Bhanja S., Shafeeque CMZ, Muvvla S., Das AK.Formulation and evaluation of mucoadhesive buccal tablets of glimepiride. Indo. Am. J.Pharm. Res., 2013, 3, 2607-24.
15. Zaki R., Hosny K., KhamesA.Ketorolac tromethamine in-situ ocular hydro gel; preparation, characterization and in-vivo evaluation., Int. J. Drug Delivery,2011, 3, 535-45.
16. Parmar V., LumbhaniA.Development and evaluation of ion-dependent in situ nasal gelling systems of metoclopramide hydrochloride as an antimigraine model drug. Int. J. Latest Res. Sci. Tech., 2012, 1, 80-89.
17. Natarajan T., ChellanVR. Formulation and characterization of anti-alzheimer’s drug loaded chitosan nanoparticles and it’s in vitro biological evaluation. J. of Youn. Pharmacists., 2015, 7,28-36.
18. Derakhshandeh K., Fathi S.Role of chitosan nanoparticles in the oral absorption of gemcitabine. Int. J. Pharma.,2011, 437, 172-77.
19. Aggarwal S., Gupta S., Dilrose P., Murthy RSR. Gemcitabine-loaded PLGA-PEG immune nanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanonotechnology., 2013, 4, 145-57.
20. Khaira R., Sharma J., Saini V. Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride. Hindawi Publishing Corporation Scientific World J.,2014, 56096, 3-8.
21. Costa, P. Modeling and comparison of dissolution profile, European journal of Pharmaceutical sciences 2001, 13, 123-133
22. Katas H., Alpar HO.Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Contr. Rel., 2016, 115, 216–225.
23. Ray M., Pal K., Anis A., Banthia AK.. Development and characterization of chitosan based polymeric hydrogel membranes. Designed Mono. and Poly., 2010,13, 193-206.
24. Zheng Y.’ Wu Y.,Yang W.Preparation, characterization and drug release in vitro of chitosan glycyrrhetic acid nanoparticles. J Pharm Sci., 2006, 95(1), 181-91.
25. Jin ML., Wei C., Wang H.;et al. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta. Pharmacologica. Sinica., 2009, 30,1337-43.
26. Dorraja, G., Moghimi, H.R. Preparation and characterization of thermoresponsive in-situ forming Poloxamer hydrogel for controlled release of nile red-loaded solid lipid nanoparticles. Iranian Journal of Pharmaceutical Sciences, 2013, 9 (4), 39- 50.
27. Betty K.S., Kelvin, W.P., Erika, P., Anne, E.C., Hitendra, P., Lee. W., Charmi, P., Robert T.D.; Terry, H.L; Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biology and Therapy 2015, 16, 43-50